Latest news with #FloPatch
Business Wire
22-07-2025
- Health
- Business Wire
Sutter Health Hospitals Deploy Wearable Ultrasound Tech to Personalize Fluid Management for Sepsis
SACRAMENTO, Calif. & LOS ANGELES--(BUSINESS WIRE)--Sutter Health, an integrated not-for-profit healthcare system based in Northern California, and Flosonics Medical today announced an expansion of the deployment of FloPatch, the first wireless wearable Doppler ultrasound device, across multiple hospital sites to support more precise and timely intravenous (IV) fluid management. This multisite deployment includes Sutter's Alta Bates Summit Medical Center, Summit Campus in Oakland and Sutter Santa Rosa Regional Hospital in Sonoma County. Implementations span the Emergency Department, Intensive Care Unit, Medical-Surgical Unit and Telemetry Unit. With these additions, six Sutter hospital campuses have now deployed FloPatch over the past year and include Sutter's Eden Medical Center in Castro Valley, Sutter's CPMC in San Francisco at CPMC Van Ness, Davies and Mission Bernal Campuses. IV fluid overload is a common complication in emergency and intensive care settings, in part because predicting a patient's response to fluids is complex. Individual needs can vary widely and shift quickly during critical illness. In studies of patients with sepsis and septic shock – a life-threatening condition caused by the body's overwhelming response to infection – nearly one-third were found to be fluid unresponsive¹. Without early identification of fluid unresponsiveness, patients may receive excessive fluids, increasing their risk of serious complications such as pulmonary edema, where fluid accumulates in the lungs. By some estimates, fluid overload can extend the average hospital stay by three days and increase healthcare costs by more than $15,000 per patient². FloPatch is an FDA-cleared, wearable device that provides clinicians with a fast and non-invasive way to perform hemodynamic assessments, measuring a patient's heart and blood flow response to IV fluids to help guide personalized fluid therapy. Clinical studies have shown that dynamic fluid assessments can reduce the need for mechanical ventilation and renal replacement therapy³,⁴, decrease ICU length of stay⁴, and are associated with lower mortality⁵. 'Our previous method of assessing fluid responsiveness was cumbersome and time-consuming. We often had to pull ICU nurses to perform evaluations in other units, which was disruptive and inefficient,' said Dr. Nader Emami, ICU medical director at Sutter Santa Rosa Regional Hospital. 'FloPatch streamlines the process with a simple, wearable device that empowers any member of the care team to perform this essential assessment faster and easier.' 'In emergency care, we often treat patients with complex needs, including people with sepsis,' said Dr. John Skovran, Emergency Department medical director at Sutter's Alta Bates Summit Medical Center, Summit Campus. 'We need a fast, reliable way to determine whether they'll benefit from fluids or be harmed by them. FloPatch gives us that clarity at the bedside in minutes, helping us make confident, timely decisions.' Joe Eibl, chief executive officer and co-founder of Flosonics Medical, noted: 'Sutter Health's multisite adoption of FloPatch reflects a growing recognition that wearable, real-time technologies play a transformative role in patient care. It's a great example of how forward-thinking health systems are meeting critical challenges with innovation.' Sutter Health prioritized staff training and thoughtfully integrated FloPatch into clinical workflows to make it a seamless part of care in intensive care and emergency medicine departments. About Sutter Health: Sutter Health is a not-for-profit healthcare system dedicated to providing comprehensive care throughout California. Committed to health equity, community partnerships, and innovative, high-quality patient care, Sutter Health is pursuing a bold new plan to reach more people and make excellent healthcare more connected and accessible. Currently serving more than 3.5 million patients, thanks to our dedicated team of more than 60,500 employees and clinicians, and 14,000+ physicians and advanced practice clinicians, with a unified focus on expanding care to serve more patients. Sutter delivers exceptional and affordable care through its hospitals, medical groups, ambulatory surgery centers, urgent care clinics, telehealth, home health, and hospice services. Dedicated to transforming healthcare, at Sutter Health, getting better never stops. Learn more about how Sutter Health is transforming healthcare at and About Flosonics Medical: Flosonics Medical is a medical device company engaged in the research and development of innovative ultrasound technology. Founded in 2015, the company's mission is to improve patient care and the practice of medicine through technology-enabled solutions and groundbreaking clinical research. For more information, please visit References: ¹ Hernández G, Ospina‑Tascón GA, Damiani LP, et al; ANDROMEDA‑SHOCK Investigators. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28‑day mortality among patients with septic shock: the ANDROMEDA‑SHOCK randomized clinical trial. JAMA. 2019 Feb 19;321(7):654–664. doi:10.1001/jama.2019.0071 ² American Hospital Directory analysis of FFY2022 Medicare IPPS (MedPAR) claims data ³ Douglas IS, Alapat PM, Corl KA, Exline MC, Forni LG, Holder AL, et al. Fluid Response Evaluation in Sepsis Hypotension and Shock: A Randomized Clinical Trial. Chest. 2020 Oct;158(4):1431–1445. doi:10.1016/ ⁴ Latham HE, Bengtson CD, Satterwhite L, et al. Stroke volume–guided resuscitation in severe sepsis and septic shock improves outcomes. J Crit Care. 2017 Dec;42:42–46. doi:10.1016/ ⁵ Dubin A, Loudet C, Kanoore Edul VS, et al. Characteristics of resuscitation, and association between use of dynamic tests of fluid responsiveness and outcomes in septic patients: results of a multicenter prospective cohort study in Argentina. Ann Intensive Care. 2020 Apr 15;10(1):40. doi:10.1186/s13613-020-00659-7
National Post
22-07-2025
- Health
- National Post
Sutter Health Hospitals Deploy Wearable Ultrasound Tech to Personalize Fluid Management for Sepsis
Article content Major California health system leads adoption of FloPatch, a device offering clinical teams real-time data to reduce the risk of giving too much or too little fluid Article content Article content both of which can lead to serious complications Article content SACRAMENTO, Calif. & LOS ANGELES — Sutter Health, an integrated not-for-profit healthcare system based in Northern California, and Flosonics Medical today announced an expansion of the deployment of FloPatch, the first wireless wearable Doppler ultrasound device, across multiple hospital sites to support more precise and timely intravenous (IV) fluid management. This multisite deployment includes Sutter's Alta Bates Summit Medical Center, Summit Campus in Oakland and Sutter Santa Rosa Regional Hospital in Sonoma County. Implementations span the Emergency Department, Intensive Care Unit, Medical-Surgical Unit and Telemetry Unit. With these additions, six Sutter hospital campuses have now deployed FloPatch over the past year and include Sutter's Eden Medical Center in Castro Valley, Sutter's CPMC in San Francisco at CPMC Van Ness, Davies and Mission Bernal Campuses. IV fluid overload is a common complication in emergency and intensive care settings, in part because predicting a patient's response to fluids is complex. Individual needs can vary widely and shift quickly during critical illness. In studies of patients with sepsis and septic shock – a life-threatening condition caused by the body's overwhelming response to infection – nearly one-third were found to be fluid unresponsive¹. Without early identification of fluid unresponsiveness, patients may receive excessive fluids, increasing their risk of serious complications such as pulmonary edema, where fluid accumulates in the lungs. By some estimates, fluid overload can extend the average hospital stay by three days and increase healthcare costs by more than $15,000 per patient². Article content FloPatch is an FDA-cleared, wearable device that provides clinicians with a fast and non-invasive way to perform hemodynamic assessments, measuring a patient's heart and blood flow response to IV fluids to help guide personalized fluid therapy. Clinical studies have shown that dynamic fluid assessments can reduce the need for mechanical ventilation and renal replacement therapy ³,⁴, decrease ICU length of stay⁴, and are associated with lower mortality⁵. Article content 'Our previous method of assessing fluid responsiveness was cumbersome and time-consuming. We often had to pull ICU nurses to perform evaluations in other units, which was disruptive and inefficient,' said Dr. Nader Emami, ICU medical director at Sutter Santa Rosa Regional Hospital. 'FloPatch streamlines the process with a simple, wearable device that empowers any member of the care team to perform this essential assessment faster and easier.' Article content 'In emergency care, we often treat patients with complex needs, including people with sepsis,' said Dr. John Skovran, Emergency Department medical director at Sutter's Alta Bates Summit Medical Center, Summit Campus. 'We need a fast, reliable way to determine whether they'll benefit from fluids or be harmed by them. FloPatch gives us that clarity at the bedside in minutes, helping us make confident, timely decisions.' Article content Joe Eibl, chief executive officer and co-founder of Flosonics Medical, noted: 'Sutter Health's multisite adoption of FloPatch reflects a growing recognition that wearable, real-time technologies play a transformative role in patient care. It's a great example of how forward-thinking health systems are meeting critical challenges with innovation.' Article content Sutter Health prioritized staff training and thoughtfully integrated FloPatch into clinical workflows to make it a seamless part of care in intensive care and emergency medicine departments. Article content About Sutter Health: Article content Sutter Health is a not-for-profit healthcare system dedicated to providing comprehensive care throughout California. Committed to health equity, community partnerships, and innovative, high-quality patient care, Sutter Health is pursuing a bold new plan to reach more people and make excellent healthcare more connected and accessible. Currently serving more than 3.5 million patients, thanks to our dedicated team of more than 60,500 employees and clinicians, and 14,000+ physicians and advanced practice clinicians, with a unified focus on expanding care to serve more patients. Article content Sutter delivers exceptional and affordable care through its hospitals, medical groups, ambulatory surgery centers, urgent care clinics, telehealth, home health, and hospice services. Dedicated to transforming healthcare, at Sutter Health, getting better never stops. Article content Learn more about how Sutter Health is transforming healthcare at and Article content About Flosonics Medical: Article content Flosonics Medical is a medical device company engaged in the research and development of innovative ultrasound technology. Founded in 2015, the company's mission is to improve patient care and the practice of medicine through technology-enabled solutions and groundbreaking clinical research. For more information, please visit Article content . Article content ¹ Hernández G, Ospina‑Tascón GA, Damiani LP, et al; ANDROMEDA‑SHOCK Investigators. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28‑day mortality among patients with septic shock: the ANDROMEDA‑SHOCK randomized clinical trial. JAMA. 2019 Feb 19;321(7):654–664. doi:10.1001/jama.2019.0071 Article content Article content ³ Douglas IS, Alapat PM, Corl KA, Exline MC, Forni LG, Holder AL, et al. Fluid Response Evaluation in Sepsis Hypotension and Shock: A Randomized Clinical Trial. Chest. 2020 Oct;158(4):1431–1445. doi:10.1016/ Article content Article content ⁴ Latham HE, Bengtson CD, Satterwhite L, et al. Stroke volume–guided resuscitation in severe sepsis and septic shock improves outcomes. J Crit Care. 2017 Dec;42:42–46. doi:10.1016/ Article content Article content Article content Article content Article content Article content Contacts Article content Media Contacts: Article content Jamie Gray, Flosonics Medical, Article content Article content Article content Article content
Business Wire
17-06-2025
- Health
- Business Wire
World's First Wearable Doppler Ultrasound Patch Expands to East Coast to Enhance Patient Safety at The Mount Sinai Hospital
LOS ANGELES--(BUSINESS WIRE)--Flosonics Medical, the leader in wearable ultrasound for critical care, today announced that The Mount Sinai Hospital has adopted FloPatch, the first wireless Doppler ultrasound device, in its surgical and transplant intensive care units. This milestone marks the company's first East Coast deployment, expanding its U.S. footprint and reinforcing growing demand for real-time, individualized fluid management in ICUs. FloPatch is an FDA-cleared, non-invasive wearable device that enables ICU clinicians to perform rapid, repeatable hemodynamic assessments to guide intravenous (IV) fluid management, a critical intervention in post-surgical care. Although fluid boluses are commonly used to treat hypotension after surgery, many patients are not fluid responsive and may face adverse effects from unnecessary fluids, leading to complications and longer hospital stays. Unlike existing tools, which can be time-consuming or invasive, FloPatch delivers real-time blood flow data at the bedside in under three minutes, helping clinicians avoid delays and make more targeted decisions. 'The wireless ultrasound device addresses a longstanding need in critical care for accessible and repeatable assessments to understand a patient's fluid responsiveness at the bedside,' said John Oropello, MD, Professor of Surgery and Medicine at the Icahn School of Medicine at Mount Sinai and Director of the Transplant ICU at Mount Sinai Hospital. 'It allows our team to make timely, physiologically guided decisions in complex, high-acuity situations.' Since introducing FloPatch in April 2025, Mount Sinai clinicians have used it to bring greater precision to fluid therapy, moving beyond protocolized care to personalized decisions grounded in real-time patient data. According to early internal data at Mount Sinai, 42% of the patients assessed with FloPatch were unresponsive to fluids, a key insight that has helped clinicians tailor treatment to meet the needs of each individual. 'Critical care ultrasound for targeted intravenous volume management is now a Society recommendation, but widespread application is limited by time, training, and inconsistency,' said Jon-Emile Kenny, MD, Chief Medical Officer and co-founder of Flosonics Medical. 'We built FloPatch to make ultrasound best practices available not only to physicians, but to nurses, nurse practitioners, physician assistants, and others involved in frontline decision-making. As the first hospital on the East Coast to adopt wearable ultrasound technology, Mount Sinai strengthens its reputation of leadership and innovation in precision medicine.' Mount Sinai's adoption of FloPatch signals a broader shift toward precision medicine in critical care. As the first hospital to implement this wearable technology in surgical and transplant ICUs, it is setting a new benchmark for individualized fluid management. Flosonics is proud to lead this innovation and support clinicians coast to coast in delivering safer, smarter care. About Flosonics Medical: Flosonics Medical is a medical device company engaged in the research and development of innovative ultrasound technology. Founded in 2015, the company's mission is to improve patient care and the practice of medicine through technology-enabled solutions and groundbreaking clinical research. For more information, please visit .
Yahoo
03-03-2025
- Business
- Yahoo
Flosonics Medical Secures $7.5 Million CAD Venture Debt from RBCx to Scale Transformative Wearable Ultrasound Technology
The funding will foster further growth and market adoption of FloPatch, the world's first wireless wearable ultrasound device designed to transform fluid management in critical care SUDBURY, Ontario, March 03, 2025--(BUSINESS WIRE)--Canadian medical device innovator, Flosonics Medical, has secured $7.5 million CAD in venture debt financing from RBCx. The financing and specialized support will accelerate Flosonics Medical's mission to improve patient outcomes through non-invasive, data-driven solutions that empower clinicians to make faster, more informed decisions at the bedside. Sepsis is a critical health challenge, affecting over 75,000 patients annually in Canada1 and 1.7 million in the U.S., with mortality rates that make it one of the leading causes of in-hospital deaths in the United States.2 Traditional Doppler ultrasound machines, which can assess blood flow and vascular conditions, can be cumbersome and time-intensive, making them less accessible in fast-paced environments such as emergency departments and intensive care units. FloPatch is a wireless, wearable Doppler ultrasound device that conducts rapid, repeatable hemodynamic assessments to understand a patient's fluid responsiveness, allowing clinicians to deliver timely and effective interventions. By streamlining critical decisions, FloPatch helps healthcare providers optimize sepsis care, reduce fluid-related complications, and improve patient outcomes. RBCx is the first tech and innovation banking arm under a Canadian bank with a dedicated life science credit advisory team that provides debt financing to pre-revenue, venture-backed life sciences companies. This type of unique servicing model provides companies like Flosonics Medical with access to capital while they scale operations and refine their innovative solutions. RBCx's venture debt financing is designed to support venture-backed life science startups at every stage of growth, from pre-clinical to commercial. In doing so, RBCx is helping to address the significant investment gaps and funding resources available in the capital-intensive sector. Led by Anne Woods, Managing Director of RBCx's national Life Sciences practice, the team combines tailored financing with strategic expertise to enable the next generation of healthcare companies. "Flosonics Medical is a great example of the transformative potential of Canada's life sciences sector, and we're longtime supporters of their mission," said Woods. "We're proud to back the scaling ambitions of companies like Flosonics Medical with the capital they need to improve patient care through bold innovations like FloPatch." With this financing, Flosonics Medical is poised to expand the reach of FloPatch and further solidify its position as a Canadian leader in life sciences innovation. "We're thrilled to be working with RBCx as we bring FloPatch to more hospitals across North America and beyond," said Joe Eibl, CEO and co-founder of Flosonics Medical. "This financing allows us to accelerate our mission of equipping healthcare providers with the tools they need to deliver the highest quality of care possible while improving operational efficiencies in hospitals." About RBC Royal Bank of Canada is a global financial institution with a purpose-driven, principles-led approach to delivering leading performance. Our success comes from the 98,000+ employees who leverage their imaginations and insights to bring our vision, values and strategy to life so we can help our clients thrive and communities prosper. As Canada's biggest bank and one of the largest in the world, based on market capitalization, we have a diversified business model with a focus on innovation and providing exceptional experiences to our more than 19 million clients in Canada, the U.S. and 27 other countries. Learn more at We are proud to support a broad range of community initiatives through donations, community investments and employee volunteer activities. See how at About RBCx RBCx – the tech and innovation banking arm of RBC - powers bold ideas, founders, and technology companies. We know building great businesses takes more than just finance, which is why our four pillars – Banking, Capital, Platform, and Ventures – combine to make us the go-to backer of Canadian innovation. We use our deep expertise to support businesses of all sizes and stages, and leverage RBC's extensive experience, networks, and capital to solve tomorrow's big problems. About Flosonics Medical Flosonics Medical is a Canadian medical device company engaged in the research and development of innovative ultrasound technology. Founded in 2015, the company's mission is to improve patient care and the practice of medicine through technology-enabled solutions and ground-breaking clinical research. For more information, please visit 1 2 View source version on Contacts For more information, please contact: Rachelle Gibson, Flosonics Medical, rgibson@ Sign in to access your portfolio
